Neoadjuvant chemoimmunotherapy improves outcomes in patients with stage III non-small cell lung cancer, suggesting enhanced treatment strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bertolaccini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: